Clinical Trial Update: Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a risk-adapted, MRD-driven strategy in untreated, fit patients with intermediate-risk chronic lymphocytic leukemia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Snippet

Sponsor: French Innovative Leukemia Organisation | Conditions: Intermediate Risk Chronic Lymphocytic Leukemia, Fit Patients | Phase 2 | Status: COMPLETED